Author | Balazs Halmos, MD | OncLive

Author | Balazs Halmos, MD

Articles

Early-Stage NSCLC Is Ripe for Change

February 13, 2019

Article

Following a 2-decade lull in early-stage lung cancer, we are now seeing much better-designed neoadjuvant and adjuvant studies based on proper biomarker selection, as well as optimized treatment choices founded upon recent advances in the metastatic setting.

Dr. Halmos on MET Mutations in Patients With NSCLC

November 15, 2016

Video

Balazs Halmos, MD, director, Thoracic Oncology, director, Clinical Cancer Genomics, Montefiore Medical Center, discusses the prevalence of MET mutations in patients with non–small cell lung cancer (NSCLC).

Dr. Halmos on Detecting Actionable Mutations in Patients With Lung Cancer

October 07, 2014

Video

Balazs Halmos, MD, section chief of Thoracic Oncology at New York-Presbyterian Hospital/Columbia University Medical Center, comments on the detection of actionable mutations in patients with lung cancer.

Dr. Halmos on the Impact of EGFR Inhibitors on the Treatment of Lung Cancer

April 28, 2014

Video

Balazs Halmos, MD, section chief of Thoracic Oncology at New York-Presbyterian Hospital/Columbia University Medical Center, discusses the impact of EGFR inhibitors on the treatment of lung cancer.

x